Pneumonia and procalcitonin levels: refining outcome prediction

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Serial procalcitonin (PCT) measurement in patients with pneumonia shows promise for predicting adverse clinical outcomes.

Why this matters

  • Largest study in North America evaluating prognostic potential of serial PCT in hospitalized patients with community acquired (CAP) or healthcare-associated pneumonia (HCAP).

Study design

  • Prospective cohort study of patients hospitalized with CAP or HCP.
  • PCT was measured on days 1-4.
  • Composite adverse outcome endpoints were all-cause mortality, ICU admission, and bacteremia.
  • Funding: bioMérieux.

Key results

  • 317 patients with CAP or HCAP.
  • 25% met the composite primary endpoint.
  • Patients with CAP requiring ICU-level care had significantly elevated PCT values on days 1 and 2, as opposed to days 3 and 4 ...